Zymeworks (NASDAQ:ZYME) Rating Increased to Strong-Buy at Citizens Jmp

Zymeworks (NASDAQ:ZYME) was upgraded by equities researchers at Citizens Jmp to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

ZYME has been the subject of a number of other reports. Zacks Research downgraded Zymeworks from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Wall Street Zen downgraded shares of Zymeworks from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Wells Fargo & Company upgraded shares of Zymeworks to a “hold” rating in a report on Friday, October 24th. B. Riley upgraded shares of Zymeworks to a “strong-buy” rating in a report on Thursday, October 9th. Finally, HC Wainwright raised shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zymeworks presently has a consensus rating of “Moderate Buy”.

Zymeworks Stock Up 1.1%

Zymeworks stock opened at $26.52 on Wednesday. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -31.57 and a beta of 1.27. Zymeworks has a twelve month low of $9.03 and a twelve month high of $28.49. The stock’s fifty day moving average is $20.00.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Zymeworks had a negative return on equity of 19.25% and a negative net margin of 47.16%.The firm had revenue of $27.61 million during the quarter, compared to analyst estimates of $28.27 million.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.